Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Open-Label, Dose-Escalation Study to Determine the Safety Tolerability & Efficacy of BMN 331 an AAV Vector-Mediated Gene Transfer of Human SERPING1 Gene in Subjects With HAE Due to Human C1-INH Deficiency
Conditions
Interventions
Dose 1 of BMN 331
Dose 2 of BMN 331
+5 more
Locations
16
United States
AllerVie Clinical Research
Birmingham, Alabama, United States
Medical Research of Arizona
Scottsdale, Arizona, United States
University of California San Diego
San Diego, California, United States
Asthma & Allergy Associates P.C.
Colorado Springs, Colorado, United States
Dr. Henry J. Kanarek Allergy, Asthma & Immunology
Overland Park, Kansas, United States
Institute For Asthma & Allergy
Chevy Chase, Maryland, United States
Start Date
February 15, 2022
Primary Completion Date
November 1, 2028
Completion Date
November 1, 2028
Last Updated
May 16, 2024
NCT05762640
NCT06628531
NCT07298447
NCT06706206
NCT07414732
NCT06960213
Lead Sponsor
BioMarin Pharmaceutical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions